Hemophilia | Pipeline Drugs update.
'Biogen and Sobi leading race to launch long-acting recombinant therapies'
By Natasha Spiller, Analyst
6 September 2013
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
Datamonitor Healthcare has reviewed the key pipeline drugs under development for the treatment of hemophilia across the US, Japan and five major EU markets (France, Germany, Italy, Spain, and the UK).
The launch of long-acting recombinant factor VIII and factor IX therapies is set to positively change treatment regimens for patients with hemophilia. However, developers of long-acting therapies face the challenge of encouraging well-managed patients to switch therapies and will need to encourage the uptake of prophylaxis within an adult population. Meanwhile, undifferentiated pipeline products will struggle to gain any headway within the hemophilia market.
- An analysis of the pipeline drugs available for the treatment of hemophilia, including an analysis of the clinical and commercial attributes of drugs to determine competitiveness in the market place.
- Datamonitor Healthcare’s interactive drug comparator tool to collectively evaluate pipeline and marketed therapies.
- These pipeline drug profiles complement Datamonitor Healthcare’s overview of the development pipeline and interactive pipeline dashboard powered by BioMedTracker.
- Eloctate (a factor VIII Fc fusion protein) and Alprolix (a factor IX Fc fusion protein), both developed by Biogen Idec and Sobi, stand to become the first recombinant fusion proteins with extended half-lives to launch in the hemophilia A and hemophilia B markets respectively.
- Pipeline therapies, such as Novo Nordisk’s turoctocog alfa, with an undifferentiated profile, will struggle to establish a foothold, particularly within the hemophilia A market. Patients whose bleeding is well-managed with current therapies will have little incentive to switch to a new therapy that does not provide clear clinical advantages.
Key questions answered
- What key therapies are under development for the treatment of hemophilia and what are their clinical and commercial attributes?
- How do the pipeline therapies compare to marketed therapies for the treatment of hemophilia?
- What are the strengths, weaknesses, opportunities and threats to pipeline drugs for hemophilia?
- Marketed Drugs: Hemophilia
(Contains Datamonitor Healthcare’s review of the marketed drugs for hemophilia)
- Epidemiology: Hemophilia
This is an Cardiovascular analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: